Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis | BioSpace

[ad_1] HORGEN, Switzerland–(BUSINESS WIRE)– Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first patient has been…

Ascending the lather to success

[ad_1] Lorelie Banguilan-LabbeFounder and Chief Executive OfficerMANO SavonCommunications professional ventures into business to seal her integration into French society as an “émigré.” ” I started a company during Covid when…